cover image: CADTH REIMBURSEMENT REVIEW - Patient and Clinician Group Input - ravulizumab (Ultomiris)

20.500.12592/ngf224n

CADTH REIMBURSEMENT REVIEW - Patient and Clinician Group Input - ravulizumab (Ultomiris)

18 Apr 2024

The information is used by CADTH in all phases of the review, including the appraisal of evidence and interpretation of the results. [...] The name of the submitting group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission. [...] Attacks to the optic nerves produce swelling and inflammation that cause symptoms of pain and loss of vision while damage to the spinal cord causes weakness or paralysis in the legs or arms, loss of sensation, and problems with bladder and bowel function. [...] The Sumaira Foundation has been involved in guideline revision discussions in the United States, at the European Union level, and in Germany; in Latin America, TSF is co-sponsoring the development of the very first NMOSD guidelines for the region in partnership with LACTRiMS (The Latin American Committee for Treatment and Research in Multiple Sclerosis). [...] The CHAMPION-NMOSD5 trial assessed the time to first on-trial relapse and associated relapse risk reduction in Ultomiris-treated patients compared with the external placebo group (i.e., from the ECU PREVENT trial).6 As noted by the study authors, there was a very strong rationale for the study design, based on important issues such as ethical considerations (i.e., the devastating impact of the sub.
Pages
19
Published in
Canada